25022
document
Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cysticercosis . Thirty-six patients with subarachnoid and intraventricular cysticercosis were randomly assigned to receive albendazole at 15 or 30 mg/kg/day plus dexamethasone for 8 days . Results favored a higher dose , with larger cyst reduction on MRI at 90 and 180 days and higher albendazole sulfoxide levels in plasma . An albendazole course at 30 mg/kg/day combined with corticosteroids is safe and more effective than the usual dose . A single treatment was insufficient in intraventricular and giant cysts .
25023
Intervention_Pharmacological
Albendazole
25024
Intervention_Pharmacological
albendazole
25025
Intervention_Pharmacological
dexamethasone
25026
Intervention_Pharmacological
albendazole
25027
Intervention_Pharmacological
corticosteroids
25028
Outcome_Physical
larger cyst reduction
25029
Outcome_Physical
albendazole sulfoxide levels in plasma
25030
Outcome_Other
safe and more effective
25031
Outcome_Other
insufficient
25032
Participant_Condition
subarachnoid and intraventricular cysticercosis
25033
Participant_Sample-size
Thirty-six
25034
Participant_Condition
subarachnoid and intraventricular cysticercosis